235 related articles for article (PubMed ID: 35895256)
1. Targeting Alternative Splicing for Therapeutic Interventions.
Centa JL; Hastings ML
Methods Mol Biol; 2022; 2537():21-36. PubMed ID: 35895256
[TBL] [Abstract][Full Text] [Related]
2. Splice-Switching Antisense Oligonucleotides Correct Phenylalanine Hydroxylase Exon 11 Skipping Defects and Rescue Enzyme Activity in Phenylketonuria.
Martínez-Pizarro A; Álvarez M; Dembic M; Lindegaard CA; Castro M; Richard E; Andresen BS; Desviat LR
Nucleic Acid Ther; 2024; 34(3):134-142. PubMed ID: 38591802
[TBL] [Abstract][Full Text] [Related]
3. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
5. Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications.
Sergeeva OV; Shcherbinina EY; Shomron N; Zatsepin TS
Nucleic Acid Ther; 2022 Jun; 32(3):123-138. PubMed ID: 35166605
[TBL] [Abstract][Full Text] [Related]
6. Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides.
Ham KA; Keegan NP; McIntosh CS; Aung-Htut MT; Zaw K; Greer K; Fletcher S; Wilton SD
Sci Rep; 2021 Jul; 11(1):15137. PubMed ID: 34302060
[TBL] [Abstract][Full Text] [Related]
7. Consensus Guidelines for the Design and
Aartsma-Rus A; Garanto A; van Roon-Mom W; McConnell EM; Suslovitch V; Yan WX; Watts JK; Yu TW
Nucleic Acid Ther; 2023 Jan; 33(1):17-25. PubMed ID: 36516128
[TBL] [Abstract][Full Text] [Related]
8. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
9. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
10. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the splice sites of a pseudoexon.
David A; Srirangalingam U; Metherell LA; Khoo B; Clark AJ
J Clin Endocrinol Metab; 2010 Jul; 95(7):3542-6. PubMed ID: 20427506
[TBL] [Abstract][Full Text] [Related]
11. Regulation of a strong F9 cryptic 5'ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides.
Balestra D; Barbon E; Scalet D; Cavallari N; Perrone D; Zanibellato S; Bernardi F; Pinotti M
Hum Mol Genet; 2015 Sep; 24(17):4809-16. PubMed ID: 26063760
[TBL] [Abstract][Full Text] [Related]
12. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2005 Oct; 5(5):467-83. PubMed ID: 16250888
[TBL] [Abstract][Full Text] [Related]
13. Progress toward therapy with antisense-mediated splicing modulation.
Du L; Gatti RA
Curr Opin Mol Ther; 2009 Apr; 11(2):116-23. PubMed ID: 19330717
[TBL] [Abstract][Full Text] [Related]
14. Antisense-mediated exon skipping to shift alternative splicing to treat cancer.
Wan J
Methods Mol Biol; 2012; 867():201-8. PubMed ID: 22454063
[TBL] [Abstract][Full Text] [Related]
15. Antisense-mediated exon inclusion.
Hua Y; Krainer AR
Methods Mol Biol; 2012; 867():307-23. PubMed ID: 22454070
[TBL] [Abstract][Full Text] [Related]
16. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
[TBL] [Abstract][Full Text] [Related]
18. Overview on applications of antisense-mediated exon skipping.
van Roon-Mom WM; Aartsma-Rus A
Methods Mol Biol; 2012; 867():79-96. PubMed ID: 22454056
[TBL] [Abstract][Full Text] [Related]
19. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
20. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
